Naval Daver, MD, University of Texas MD Anderson Cancer Center, Houston, TX, outlines findings from a Phase I/IIb study investigating the efficacy and safety of magrolimab, azacitidine and venetoclax in patients with acute myeloid leukemia (AML). Overall, the three-drug combination was well-tolerated and elicited minimal myelosuppression, with patients also achieving a higher overall survival (OS) than with standard treatment. With many patients in this study harboring a TP53 mutation, Dr Daver believes that this novel combination could be considered in the frontline setting in the future, however, further investigation is required to fully understand the impact of TP53 mutation on the efficacy of this regimen. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.